Acemetacin for active axial spondyloarthritis
Part of Bones, joints & muscles clinical trials.
This trial tests a pain-relieving drug called acemetacin for people with axial spondyloarthritis (a type of arthritis affecting the spine and pelvis). The drug aims to reduce pain and inflammation, and this study will see how well it works in real life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have axial spondyloarthritis that is active (causing symptoms).
- You are not allergic to acemetacin or similar pain relievers (like ibuprofen).
- You do not have active stomach ulcers or a history of frequent ulcers or bleeding.
- You have not used certain strong treatments (steroids or targeted therapy) in the last 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medication (called 608) to see if it helps reduce pain and inflammation in people with a type of spinal arthritis that isn't visible on X-rays. If you have persistent back pain and signs of inflammation, this treatment might offer a new option to feel better.
This study tests a new medicine called 608 for people with non-radiographic axial spondyloarthritis (a type of inflammatory back pain). The goal is to see if it can reduce pain and inflammation.
This trial tests whether taking nonsteroidal anti-inflammatory drugs (NSAIDs) helps people with axial spondyloarthritis stay in remission and avoid future flare-ups. It’s meant to see if NSAIDs can reduce the chance of symptoms returning and keep disease activity low over time.
This trial tests whether tofacitinib (a pill that reduces inflammation) can help people with early-stage axial spondyloarthritis, a type of arthritis that mainly affects the spine and pelvis. It's for those who have had symptoms for 2 years or less and have active disease with signs of inflammation in MRI or blood tests.
This trial tests a new medication called vilamakitug to see if it can reduce pain and inflammation in people with axial spondyloarthritis, a type of arthritis that affects the spine and joints. It may help those who haven't found relief with other treatments.
This study follows people with certain types of inflammatory arthritis (spondyloarthritis) to learn more about how the disease progresses and how it affects patients over time. Joining this study could help researchers understand the condition better and improve future care.
Hear when a new Axial Spondyloarthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.